Biotron Ltd
BIT
Company Profile
Business description
Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.
Contact
56 Delhi Road
Suite 3.3
North Ryde
SydneyNSW2113
AUST: +61 298050488
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
4
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
Current operating conditions are challenging but over the long-term prospects are better.
stocks
Why Guzman and Reece's share reversals have a lot in common
Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,477.30 | 20.70 | -0.24% |
| CAC 40 | 8,143.92 | 92.85 | 1.15% |
| DAX 40 | 22,794.11 | 383.84 | 1.71% |
| Dow JONES (US) | 43,422.20 | 39.01 | -0.09% |
| FTSE 100 | 8,706.59 | 37.92 | 0.44% |
| HKSE | 23,787.93 | 753.91 | 3.27% |
| NASDAQ | 19,013.33 | 13.06 | -0.07% |
| Nikkei 225 | 38,142.37 | 95.42 | -0.25% |
| NZX 50 Index | 12,452.46 | 145.19 | 1.18% |
| S&P 500 | 5,946.62 | 8.63 | -0.14% |
| S&P/ASX 200 | 8,240.70 | 11.20 | -0.14% |
| SSE Composite Index | 3,380.21 | 34.17 | 1.02% |